StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Ketorolac

HCID 3826
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
66635-83-4
Standard-SMILES
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
InChIKey
OZWKMVRBQXNZKK-UHFFFAOYSA-N
Summenformel
C15H13NO3
Durchschnittliche Molmasse
255,27 g/mol
Monoisotopische Masse
255,08954328

Überblick

Ketorolac is a racemate comprising equimolar amounts of (R)-(+)- and (S)-()-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-() enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure. It has a role as a non-steroidal anti-inflammatory drug, an analgesic, a cyclooxygenase 2 inhibitor and a cyclooxygenase 1 inhibitor. It contains a (R)-ketorolac and a (S)-ketorolac. It is a conjugate acid of a ketorolac(1-).

Namen und Bezeichner

Bevorzugter Name
Ketorolac
IUPAC
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
Englischer Name
Ketorolac
Summenformel
C15H13NO3
Molmasse
255.27

Namen und Synonyme

ketorolac74103-06-3KetorolacoKetorolacum(+-)-Ketorolacrac-ketorolacDTXSID8023189(+-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acidCHEBI:6129YZI5105V0L1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydroDTXCID503189
Weitere Namen anzeigen
Ketorolac acidFluoxetinAcular(S)-KetorolacDolacrs37619LixidolTm-asynToratex
1H-Pyrrolizine-1-carboxylic acid, 2,3-dihydro-5-benzoyl-, (+-)-5-(benzoyl)-2,3-dihydro-1H-pyrrolizine-1-carboxylic acidRefChem:55433M01AB15S01BC055-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acidKetoralac66635-83-4

Datenbank-Bezeichner

CAS
66635-83-4、74103-06-3
PubChem CID
3826
DTXSID
DTXSID8023189
ChEMBL
CHEMBL469
ChEBI
CHEBI:6129

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
1,9
Polarare Oberfläche (TPSA)
59,3 Ų
H-Brücken-Donoren
1
H-Brücken-Akzeptoren
3
Frei drehbare Bindungen
3
Schwere Atome
19
Formalladung
0
Komplexität
376

Experimentelle und physikochemische Eigenschaften

Drugs · 2 Einträge

Pharmaceuticals -> Analgesics and anti-inflammatories

Pharmaceuticals

LogP · 2 Einträge

2.1

2.72

Solubility5.13e-01 g/L
Human Drugs · 2 Einträge

Breast Feeding; Lactation; Milk, Human; Analgesic Agents; Anti-inflammatory Agents, Nonsteroidal

Pharmaceuticals

Melting Point · 2 Einträge

162-165 °C (tromethamine salt)

165 - 167 °C (tromethamine salt)

Physical DescriptionSolid
Dissociation Constants · 2 Einträge

3.49

3.5

Physikochemische Eigenschaften

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Danger

H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]

P261, P264, P264+P265, P270, P271, P280, P301+P316, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 7 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Regulatory InformationREACH registered substance: 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid (EC: 616-049-1)
Hazard Classes and CategoriesAcute Tox. 3 (100%)

Toxikologische Informationen

Hepatotoxicity · 1 Eintrag

Prospective studies show that up to 1% of patients taking ketorolac experience at least transient serum aminotransferase elevations. These may resolve even with drug continuation. Marked aminotransferase elevations above 3 times the upper limit of normal (ULN) occur in less than 1% of patients. Clinically apparent liver injury with jaundice from ketorolac has not been described in any detail so that the latency, clinical features and prognosis of injury is unknown. Ketorolac is not mentioned as an etiologic agent in large case series on drug induced liver injury or acute liver failure from the United States. However, the antiplatelet activity of ketorolac can lead to complications mostly due to platelet dysfunction and bleeding, and several instances of hepatic rupture and subcapsular hepatic hematomas have been reported with its use which might present clinically as acute liver injury.

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 5 Einträge

S01BC05

M - Musculo-skeletal system

S - Sensory organs

QM - Musculo-skeletal system

QS - Sensory organs

Protein Binding>99% of Ketorolac is plasma protein bound.
Pharmacodynamics · 1 Eintrag

Ketorolac is a non-selective NSAID and acts by inhibiting both COX-1 and COX-2 enzymes which are normally responsible for converting arachidonic acid to prostaglandins. The COX-1 enzyme is constitutively active and can be found in platelets, gastric mucosa, and vascular endothelium. On the other hand, the COX-2 enzyme is inducible and mediates inflammation, pain and fever. As a result, inhibition of the COX-1 enzyme is linked to an increased risk of bleeding and risk of gastric ulceration, while the desired anti-inflammatory and analgesic properties are linked to inhibition of the COX-2 enzyme. Therefore, despite it's effectiveness in pain management, ketorolac should not be used long-term since this increases the risk of serious adverse effects such as gastrointestinal bleeding, peptic ulcers, and perforations.

Mechanism of Action · 1 Eintrag

Ketorolac inhibits key pathways in prostaglandin synthesis which is crucial to it's mechanism of action. Although ketorolac is non-selective and inhibits both COX-1 and COX-2 enzymes, it's clinical efficacy is derived from it's COX-2 inhibition. The COX-2 enzyme is inducible and is responsible for converting arachidonic acid to prostaglandins that mediate inflammation and pain. By blocking this pathway, ketorolac achieves analgesia and reduces inflammation. Ketorolac is administered as a racemic mixture; however, the "S" enantiomer is largely responsible for it's pharmacological activity.

Biological Half-Life · 1 Eintrag

Ketorolac tromethamine is administered as a racemic mixture, therefore the half-life of each enantiomer must be considered. The half life of the S-enantiomer is ~2.5 hours, while the half life of the R-enantiomer is ~5 hours. Based on this data, the S enantiomer is cleared about twice as fast as the R enantiomer.

Zugehörige Reaktionen

15
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 372229
HRID 372229als Edukt
Reaktionsgleichung von HRID 430837
HRID 430837als Produkt
Reaktionsgleichung von HRID 430838
HRID 430838als Edukt
Reaktionsgleichung von HRID 434532
HRID 434532als Edukt
Reaktionsgleichung von HRID 636077
HRID 636077als Edukt
Reaktionsgleichung von HRID 636078
HRID 636078als Edukt
Reaktionsgleichung von HRID 636079
HRID 636079als Edukt
Reaktionsgleichung von HRID 636080
HRID 636080als Edukt
ZurückSeite 1 von 2

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
UNII
YZI5105V0L
EC Number
616-049-1
Nikkaji
J1.487.487I
Schmelzpunkt
160 · 160-161°C
Siedepunkt
493.2 · 493.2±40.0 °C(Predicted)
Dichte
1.33 · 1.33±0.1 g/cm3(Predicted)
storage temp.
2 · 2-8°C
Löslichkeit
Chloroform (Slightly), Methanol (Slightly)
Aggregatzustand
Solid
pka
3.49 · 3.49 ±0.02(at 25℃)
Farbe
Off-White
Wasserlöslichkeit
183 mg/L · 183mg/L(32 ºC)
InChI
InChI=1S/C15H13NO3/c17-14(10-4-2-1-3-5-10)13-7-6-12-11(15(18)19)8-9-16(12)13/h1-7,11H,8-9H2,(H,18,19)
InChIKey
OZWKMVRBQXNZKK-UHFFFAOYSA-N
SMILES
N12CCC(C(O)=O)C1=CC=C2C(=O)C1=CC=CC=C1
CAS Datenbank
74103 · 74103-06-3(CAS DataBase Reference)
EPA chemische Informationen
1 H-Pyrrolizine-1-carboxylic · 1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro- (74103-06-3)
Adverse EffectsDrug-Drug Interactions
Toxicity Summary · 1 Eintrag

High quantities or prolonged use of ketorolac can lead to hepatotoxicity and nephrotoxicity. In addition, ketorolac can cause multiple skin disorders, such as toxic epidermal necrolysis. Anaphylactic shock has been characterized due to ketorolac overdose.

Drug Induced Liver Injury · 6 Einträge

Benchmark Dataset for the Liver Toxicity Knowledge Base (LTKB)

ketorolac

Toradol®

NSAIDs

3

less-DILI-concern drugs

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Sicherheitsdaten

ridadr
3249
hs_code
2933998090
Toxizität
LD50 orally in mice: ~200 mg/kg (Rooks)
hazard_class
6.1(a)
packing_group
II
Metabolism/Metabolites · 1 Eintrag

Ketorolac is heavily metabolized via hydroxylation or conjugation in the liver; however, it appears that the key metabolic pathway is glucuronic acid conjugation. Enzymes involved in phase I metabolism include CYP2C8 and CYP2C9, while phase II metabolism is carried out by UDP-glucuronosyltransferase (UGT) 2B7.

FDA Pharmacological Classification · 6 Einträge

YZI5105V0L

KETOROLAC

Mechanisms of Action [MoA] - Cyclooxygenase Inhibitors

Chemical Structure [CS] - Anti-Inflammatory Agents, Non-Steroidal

Established Pharmacologic Class [EPC] - Nonsteroidal Anti-inflammatory Drug

Established Pharmacologic Class [EPC] - Cyclooxygenase Inhibitor

MeSH Pharmacological Classification · 2 Einträge

Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.

Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes.

Absorption, Distribution and Excretion · 4 Einträge

Ketorolac is rapidly, and completely absorbed after oral administration with a bioavailability of 80% after oral administration. Cmax is attained 20-60 minutes after administration, and after intramuscular administration, the area under the plasma concentration-time curve (AUC) is proportional to the dose administered. After intramuscular administration, ketorolac demonstrates a time to maximal plasma concentration (tmax) of approximately 45-50 minutes, and a tmax of 30-40 minutes after oral administration. The rate of absorption may be reduced by food; however, the extent of absorption remains unaffected.

Ketorolac is primarily renally eliminated and approximately 92% of the dose can be recovered in the urine with 60% of this proportion recovered unchanged, and 40% recovered as metabolites. In addition 6% of a single dose is eliminated in the feces.

The apparent volume of distribution of ketorolac in healthy human subjects is 0.25 L/kg or less.

The plasma clearance of ketorolac is 0.021 to 0.037 L/h/kg. Further, studies have illustrated that clearance of oral, IM and IV doses of ketorolac are comparable which suggests linear kinetics. It should also be noted that clearance in children is about double the clearance found in adults.

Cellular LocationsCytoplasm
Metabolite PathwaysKetorolac Action Pathway

Verwendung und Herstellung

UsesUse (kg) in USA (2002): 591
Use ClassificationPharmaceuticals

Anwendungen

Verwendenantiarrhythmic

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

Natriumhydrid2-AminoethanolOctanEssigsäureanhydridN,N-DimethylformamidPyrrolBromoacetaldehydeAcetylacetoneManganese(II) acetate tetrahydrateDimethylsulfidN-ChlorsuccinimidDimethylglutaratKaliumpermanganatEssigsureEsterified product2-BenzoylpyrroleDichlorethanMonoester